Medicare Continues Hemp Program for Seniors Despite Looming Federal Limits
Washington, Saturday, 23 May 2026.
Following a recent court dismissal, Medicare will continue its controversial pilot program offering seniors up to $500 annually in hemp products, despite strict federal restrictions looming this November.
A Legal Victory for the Medicare Pilot
In mid-to-late May 2026, Judge Trevor N. McFadden of the United States District Court for the District of Columbia dismissed a lawsuit seeking to halt the Centers for Medicare and Medicaid Services (CMS) hemp coverage initiative [1][2] [alert! ‘Sources differ on the exact dismissal date: May 16 versus May 22’]. The lawsuit, brought by prohibitionist group Smart Approaches to Marijuana (SAM) and pharmaceutical developer MMJ International Holdings, was dismissed because the plaintiffs failed to demonstrate sufficient injury to establish legal standing [1][2]. The dismissal follows an April 2026 legal brief filed by Health and Human Services Secretary Robert F. Kennedy Jr. and CMS Director Dr. Mehmet Oz, who successfully argued that the plaintiffs’ claims were too abstract to warrant judicial intervention [2].
The Regulatory Collision Course
While the judicial dismissal allows the CMS program to proceed, it highlights a stark contradiction in federal policy. On November 12, 2025, Congress enacted Section 781 of the Continuing Appropriations and Extensions Act of 2026 [1]. This legislation strictly redefined hemp, capping finished products at a maximum of 0.4 milligrams of total THC per container [1][3]. When enforcement of this new standard begins on November 12, 2026, it is projected to eliminate approximately 95 percent of current consumable hemp products from the market [3]. This creates a regulatory paradox: a federal health agency is actively funding senior access to products that congressional mandates will effectively ban in less than 6 months [1][3].
Executive Action and Market Uncertainty
The CMS pilot program is deeply intertwined with broader executive branch efforts to reshape federal cannabis policy. The initiative stems from a December 2025 executive order issued by President Donald Trump, which directed agencies to finalize the federal rescheduling of marijuana and improve access to full-spectrum CBD products [2]. This executive push was further emphasized on April 23, 2026, when President Trump used the Truth Social platform to urge Congress to protect CBD access, framing it as a necessary measure for patients and American farmers [3]. Furthermore, the Department of Justice has scheduled a hearing for June 29, 2026, to formally consider moving marijuana from Schedule I to Schedule III [3], a classification shared with prescription medications like Tylenol with codeine [4].